PT  - JOURNAL ARTICLE
AU  - Liao, Felix Haifeng
AU  - Lowry, Michael
TI  - Speeding and Traffic-Related Injuries and Fatalities during the 2020 COVID-19 Pandemic: The Cases of Seattle and New York City
AID  - 10.1101/2021.08.08.21261745
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.08.21261745
4099  - http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261745.short
4100  - http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261745.full
AB  - Despite fewer cars on roads during the COVID-19 pandemic, deaths associated with motor vehicle collisions in New York City and Seattle remained largely unchanged in 2020. Using police data on weekly counts of collisions, we compared trends in 2020 with those of 2019, while controlling for the reduction of traffic volumes and seasonal weather conditions. Results of difference-in-differences estimation suggest that during the early months of the pandemic, or March-May, the incidence rates of severe or fatal injury crashes related to speeding increased by nearly 8 times in Seattle and more than 4 times in New York City. In the rest of 2020, they were still significantly higher than what would be expected in the absence of the pandemic. This research suggests that in similar situations that depress travel demand (e.g., another pandemic), policymakers should formulate plans to reduce speeding which may prevent an upswing in severe injuries and fatalities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study used publicly available and deidentified secondary data reported on an aggregated level. Therefore, ethics approval was not required.Funding StatementThis study was funded by a grant from Pacific Northwest Transportation Consortium (Pac Trans), USDOT Transportation Center for Federal Region 10 under the award #69A3551747110.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used publicly available and deidentified secondary data reported on an aggregated level. Therefore, ethics approval was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable